Potential Role of Curcumin for the Treatment of Major Depressive Disorder.
- Published in:
- CNS Drugs, 2022, v. 36, n. 2, p. 123, doi. 10.1007/s40263-022-00901-9
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 2
Results: 9
1
2
Alternative Routes of Administration of Clozapine.
- Published in:
- CNS Drugs, 2022, v. 36, n. 2, p. 105, doi. 10.1007/s40263-022-00900-w
- By:
- Publication type:
- Article
3
Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
- Published in:
- CNS Drugs, 2022, v. 36, n. 2, p. 181, doi. 10.1007/s40263-022-00899-0
- By:
- Publication type:
- Article
4
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
- Published in:
- CNS Drugs, 2022, v. 36, n. 2, p. 113, doi. 10.1007/s40263-022-00896-3
- By:
- Publication type:
- Article
5
Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies.
- Published in:
- CNS Drugs, 2022, v. 36, n. 2, p. 167, doi. 10.1007/s40263-021-00894-x
- By:
- Publication type:
- Article
6
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
- Published in:
- CNS Drugs, 2022, v. 36, n. 2, p. 191, doi. 10.1007/s40263-021-00893-y
- By:
- Publication type:
- Article
7
Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
- Published in:
- 2022
- By:
- Publication type:
- Letter
8
Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
- Published in:
- 2022
- By:
- Publication type:
- Letter
9
Pharmacological Management of Apathy in Dementia.
- Published in:
- CNS Drugs, 2022, v. 36, n. 2, p. 143, doi. 10.1007/s40263-021-00883-0
- By:
- Publication type:
- Article